Ian Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ian Flinn, MD, PhD
Advertisement
Articles by Ian Flinn, MD, PhD
A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.
Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).
Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the iNNOVATE trial in Waldenstrom macroglobulinemia.
Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the RELEVANCE trial in follicular lymphoma.
Advertisement
Latest Updated Articles
Dr. Flinn on the Utility of Tafasitamab in Relapsed/Refractory DLBCLPublished: June 12th 2020 | Updated:
Dr. Flinn on the RELEVANCE Trial in Follicular LymphomaPublished: July 17th 2018 | Updated:
Dr. Flinn on the iNNOVATE Trial in Waldenstrom MacroglobulinemiaPublished: August 8th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5